Research graph
References from Retraction notice to “SMYD3 induces sorafenib resistance by activating SMAD2/3-mediated epithelial-mesenchymal transition in hepatocellular carcinoma” [iScience 26 (2023) 106994]. Local targets link to admitted publications; unresolved targets remain external evidence.
